Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals

Rhea-AI Summary

Vivos (OTCQB: RDGL) announced U.S. Patent No. 12,521,452 B2 issued January 13, 2026, for a radiotherapy thermogel and received PRECISIONGEL™ trademark approvals in the United States and New Zealand.

The patent protects PRnT platform innovations using a biodegradable PLGA-g-PEG thermosensitive hydrogel with yttrium-90 particles for localized beta radiation delivery into solid tumors. A new patent application expands claims to use the hydrogel as a carrier for anti-cancer agents, gene therapy agents, proteins, peptides, and timed release delivery.

Positive

• U.S. patent issued: 12,521,452 B2 on January 13, 2026
• PRECISIONGEL™ trademark approved for publication in US and New Zealand
• New patent application expands hydrogel use to drug and gene delivery

Negative

• No financial impact or revenue guidance disclosed to quantify IP value

News Market Reaction – RDGL

-7.02%

1 alert

-7.02% News Effect

On the day this news was published, RDGL declined 7.02%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Kennewick, WA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a pioneer in innovative cancer treatment technologies, announces the issuance of U.S. Patent No. 12,521,452 B2 by the United States Patent and Trademark Office (USPTO), titled “Radiotherapy Gel and Method of Preparing the Same.” The patent, granted on January 13, 2026, protects critical advancements in the company’s proprietary Precision Radionuclide Therapy^TM (PRnT) platform, underpinning its flagship products RadioGel ^® (for human applications) and IsoPet ^® (for veterinary use).

The patent covers a novel radioactive thermogel suspension featuring a biodegradable, thermosensitive PLGA-g-PEG hydrogel combined with insoluble yttrium phosphate particles incorporating yttrium-90 (⁹⁰Y), as well as insoluble particles of other isotopes that could be used with the hydrogel to deliver precise, localized radiation directly into solid tumors or cancerous tissues. These innovations enable precise, localized beta radiation delivery directly into solid tumors, with the gel remaining injectable at room temperature and solidifying rapidly at body temperature to immobilize the radiation source—minimizing exposure to healthy tissue.

In parallel, the company’s PRECISIONGEL^™ trademark has been approved for publication in both the United States and New Zealand. Additionally, Vivos has filed a new patent application further protecting its PrecisionGel hydrogel technology. The new application covers the use of the hydrogel as a carrier for delivery of a range of therapeutic agents such as anti-cancer agents, gene therapy agents, proteins, peptides, etc. and for timed release of such agents once formed into a gel after injection, reinforcing its position in advanced hydrogel-based delivery systems.

“These milestones— the patent issuance, trademark approvals, and new filing—materially enhance the strength and scope of our intellectual property estate and extend our patent protection well into the future,” said Dr. Mike Korenko, CEO of Vivos Inc. “Building a defensible IP position remains a core strategy to drive shareholder value, support ongoing clinical progress, enable global commercial expansion, and position the company favorably for potential strategic partnerships or other opportunities.”

About Vivos Inc.
Vivos Inc. is a clinical-stage medical device company developing RadioGel^®, a precision radiotherapy hydrogel for human and veterinary oncology applications. IsoPet^® is commercially available for veterinary use in certified clinics nationwide.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated. These risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

CONTACT:

Mike Korenko, ScD	Brad Weeks
CEO, Vivos Inc	President, Vivos Inc
mkorenko@radiogel.com	Brad.Weeks@vivosinc.com

Follow Vivos Inc. on X (Twitter): @VivosIncUSA

Learn more about RadioGel^® and IsoPet^® at www.VivosInc.com

FAQ

What did Vivos (RDGL) patent issuance on January 13, 2026 cover?

The patent covers a radiotherapy thermogel that delivers localized beta radiation into tumors. According to the company, U.S. Patent No. 12,521,452 B2 protects a PLGA-g-PEG hydrogel containing yttrium-90 and other isotope particles for injectable tumor therapy.

How does the patented Vivos (RDGL) thermogel work in cancer treatment?

The thermogel is injectable at room temperature and solidifies at body temperature to immobilize radioisotopes. According to the company, this enables precise, localized beta radiation delivery to solid tumors while minimizing healthy tissue exposure.

What is the significance of PRECISIONGEL™ trademark approvals for Vivos (RDGL)?

Trademark approvals support brand protection for the hydrogel technology in key jurisdictions. According to the company, PRECISIONGEL™ approvals in the US and New Zealand help safeguard commercialization and global expansion plans for its hydrogel platform.

What does Vivos (RDGL) new patent application add to its IP estate?

The new application covers using the hydrogel as a carrier for therapeutic agents and timed release. According to the company, claims include delivery of anti-cancer agents, gene therapy agents, proteins, peptides, and other therapeutics after injection.

Will the new Vivos (RDGL) patents immediately affect revenue or partnerships?

The announcement did not state immediate revenue or partnership outcomes from the patents. According to the company, the filings are intended to strengthen IP for clinical progress and potential strategic partnerships, but no financial guidance was provided.